More on Spectrum Pharmaceuticals ([SPPI]] +1%) Q4: net profit edges up to $8.6M as revenues...

|By:, SA News Editor

More on Spectrum Pharmaceuticals ([SPPI]] +1%) Q4: net profit edges up to $8.6M as revenues essentially remain flat for the third quarter in a row. Top line hurt by falling sales of Fusilev (colon), which drop 14% Q/Q to $44.6M, possibly due to resupply of cheaper leucovorin generic. Forecasts increase in 2013 revenue and operating income but doesn't provide specific guidance.